Publications by authors named "Oki Taniyama"
Article Synopsis
- GPNMB, a protein expressed in macrophages, is linked to liver recovery following acute liver injury (ALI) in mice and is studied for its role in human ALI and acute liver failure (ALF).
- The study assessed serum GPNMB levels over time in 56 ALI/ALF patients, revealing higher GPNMB levels associated with severe conditions like hepatic encephalopathy and adverse outcomes such as liver transplantation or death.
- Findings suggest that elevated serum and liver GPNMB correlate with liver injury severity and prognosis, with GPNMB-positive macrophages presenting an immunosuppressive M2c phenotype, highlighting its potential as a prognostic marker for ALI and ALF patients.
Objective: The present study aimed to reveal the factors associated with virologic failure in sofosbuvir and ledipasvir (SOF/LDV)-treated patients, and identify baseline NS5A or NS5B resistance-associated substitutions (RASs).
Methods: Four hundred ninety-three patients with Hepatitis C Virus (HCV) genotype 1b infection were treated with SOF/LDV; 31 had a history of interferon (IFN)-free treatment with daclatasvir and asunaprevir. The effect of baseline RASs on the response to SOF/LDV therapy was analyzed.
Background And Aim: We confirmed the clinical utility of a three-dimensional navigation system during transarterial chemoembolization.
Methods: We evaluated 128 tumors in 91 patients enrolled between May 2015 and August 2016. We evaluated the accuracy of the three-dimensional navigation imaging system for all tumors.
Background: Daclatasvir (DCV) and asunaprevir (ASV) combination therapy has been primarily used in patients without NS5A L31 or Y93 resistance-associated substitutions (RASs) before treatment. We examined the characteristics of patients without these baseline RASs who did not achieve hepatitis C virus eradication with DCV and ASV combination therapy and identified new baseline NS5A RASs that are closely associated with failure of combination therapy.
Methods: Three hundred thirty-five patients with hepatitis C virus genotype 1 infection with no NS5A L31, NS5A Y93, and NS3 D168 RASs before DCV and ASV combination therapy and no history of protease inhibitor therapy were enrolled.